Oral delivery is convenient. It is also one of the hardest delivery routes for peptide compounds.

The central problem is not simply that peptides are “fragile”. Oral bioavailability depends on several separate events:

1. The peptide must remain chemically intact in the stomach and intestine.
2. It must pass through the mucus layer.
3. It must cross the intestinal epithelium.
4. It must avoid premature efflux and metabolism.
5. Enough intact, active compound must reach systemic circulation to be measured reliably.

Most linear peptides fail at more than one of these stages. Research published in 2026 continues to support a clear conclusion: oral peptide delivery is possible, but it normally requires deliberate molecular design and sophisticated formulation. Simply placing an injectable peptide into a capsule does not create an effective oral compound.

This article explains the main barriers and the research strategies being developed to address them.

Research note: This article is for scientific and laboratory research context only. It does not provide medical advice or instructions for human administration.

The first barrier: enzymatic degradation in the GI tract

Peptides are chains of amino acids joined by peptide bonds. Those same bonds are recognised by the digestive system as substrates for breakdown.

In the stomach, low pH and the protease pepsin can begin degrading susceptible peptide structures. Once the material reaches the small intestine, it is exposed to pancreatic proteases, including trypsin and chymotrypsin, as well as brush-border peptidases located close to the intestinal epithelium.

The result is a reduction in the intact fraction of the swallowed dose.

This distinction matters. Detecting amino acids or short fragments after oral administration does not demonstrate that the original peptide reached circulation intact. Analytical methods must distinguish the parent compound from degradation products. For that reason, oral peptide studies often require sensitive LC-MS or LC-MS/MS methods capable of identifying intact material and relevant metabolites.

The GI environment also changes continuously. pH, bile salts, food components, transit time, ionic strength and endogenous proteins can all influence peptide stability. A formulation that performs well in a simple buffer may behave very differently in simulated gastric fluid, intestinal fluid or an animal model.

The 2026 review Navigating the complexity of oral peptide delivery describes this as a combined stability and exposure problem rather than a single enzyme issue. Peptide aggregation, physicochemical instability and proteolysis can reduce the available dose before absorption begins.[^1]

The second barrier: mucus and epithelial permeability

Survival is only the first requirement.

Peptides are generally larger, more polar and more highly charged than conventional small-molecule drugs. These properties can make them difficult to diffuse through intestinal mucus and difficult to partition into the cell membrane.

The intestinal epithelium is designed to regulate transport. Tight junctions connect adjacent epithelial cells and restrict movement through the paracellular route. Transcellular movement through the cells is also limited by membrane properties, transporters and intracellular processing.

In practical terms, a peptide can reach the intestinal surface and still fail to cross it in a meaningful quantity.

This is why oral bioavailability is often reported below 1% for unmodified peptides in experimental models. The figure is not a universal constant. It varies with sequence, size, structure, dose, formulation, species and analytical method. However, it illustrates the scale of the challenge.

A useful way to view oral absorption is as a sequence of filters:

Stage	Main question
Luminal stability	Does the peptide remain intact in gastric and intestinal conditions?
Mucus transport	Can it move through the mucus layer without becoming trapped?
Epithelial permeability	Can it cross the intestinal cell layer?
Intracellular handling	Is it degraded, retained or transported by the cells?
First-pass processes	Is it removed by intestinal or hepatic metabolism?
Systemic exposure	Can intact compound be measured in circulation?

Failure at any stage can produce low or highly variable exposure.

Why a short peptide is not automatically an oral peptide

Shorter sequences can have advantages. A smaller peptide may be less sterically hindered and may interact with transporters or epithelial surfaces differently from a larger molecule.

However, short does not mean orally bioavailable.

KPV is a useful research example because it is a tripeptide fragment composed of lysine, proline and valine. Its small size makes it relevant to studies of peptide transport and local gut biology. Previous research has explored the role of the PepT1 oligopeptide transporter in KPV-related epithelial research.

That does not establish reliable systemic exposure after oral administration. It demonstrates why sequence-specific investigation is necessary. A peptide may be relevant to gut-focused research while still having limited oral bioavailability as an intact circulating compound.

The same principle applies to larger molecules. BPC-157, one of the most extensively discussed injectable research peptides, is commonly investigated through non-oral routes. Its prominence in research discussions should not be confused with evidence that a conventional oral formulation can deliver intact BPC-157 systemically.

Route, formulation and analytical verification must remain separate questions.

What formulation science is trying to solve

The 2026 research direction is moving away from single-technology solutions. Instead, development programmes are combining several mechanisms to address different biological barriers at the same time.

1. Enteric coatings

Enteric coatings are designed to delay release until the dosage form reaches a higher-pH region of the intestine. This can reduce exposure to gastric acid and pepsin.

The approach is useful when the peptide is particularly acid-labile. It does not, by itself, solve intestinal proteolysis or epithelial permeability. An enteric coating may protect the compound during transit and still produce little systemic exposure if the released peptide cannot cross the intestinal wall.

Release location also matters. The coating must dissolve at the intended site, and the peptide must remain co-localised with any permeation enhancer or stabilising excipient after release.

2. Lipid-based systems

Lipid-based formulations include liposomes, lipid nanoparticles, self-emulsifying systems and other carrier structures.

They may help by:

• shielding peptide molecules from the aqueous GI environment;
• reducing aggregation;
• improving interaction with cell membranes;
• modifying dissolution and release;
• supporting transport through lipid-associated pathways.

Lipidisation is a separate strategy. This involves chemically attaching a lipid or fatty-acid chain to the peptide. It can increase membrane interaction and alter pharmacokinetics, but it also changes the molecule itself. The modified structure must retain the required research activity and remain sufficiently stable during manufacture, storage and testing.

These systems are promising, but “liposomal” is not a substitute for evidence. Performance must be assessed using stability studies, release testing, permeability assays and pharmacokinetic analysis.

3. Permeation enhancers

Permeation enhancers are excipients intended to increase epithelial transport. Examples studied in oral peptide research include medium-chain fatty acids such as sodium caprate, as well as salcaprozate sodium, commonly known as SNAC.

Depending on the system, these compounds may:

• increase transcellular membrane fluidity;
• temporarily influence tight-junction behaviour;
• create a local pH environment;
• reduce certain forms of proteolytic activity;
• improve peptide interaction with the epithelial membrane.

Their effects are compound-specific and concentration-dependent. An enhancer that improves absorption for one peptide may have little effect on another. The interaction can also vary between in vitro models, animals and humans.

The clinical examples of oral semaglutide and oral octreotide demonstrate that oral peptide delivery can work under tightly controlled formulation conditions. They do not demonstrate that every peptide can be made orally effective with the same excipient.

Pharmacokinetic variability remains a major limitation

Even when oral exposure is measurable, it may be inconsistent.

Variability can result from:

• gastric emptying rate;
• fed or fasted state;
• intestinal pH;
• bile salt concentration;
• transit time;
• mucus thickness;
• microbiome-related metabolism;
• differences in epithelial transporter expression;
• formulation disintegration and dissolution;
• species-specific GI physiology.

This is one reason why animal data must be interpreted carefully. A formulation may produce strong exposure in a rodent or dog model but perform differently in humans. The 2026 literature highlights differences in gastric pH, tight-junction structure, mucus behaviour and tolerable excipient concentrations as important translational variables.[^1]

For serious research, the relevant question is not simply “did the peptide work orally?” It is:

Which intact species was measured, in which model, at what exposure, and under which formulation conditions?

The 2026 role of computational and AI-driven prediction

Computational methods are increasingly being used to reduce the number of formulation combinations that require physical testing.

Current research areas include:

• predicting protease cleavage sites from peptide sequence and structure;
• modelling peptide aggregation in biorelevant fluids;
• estimating membrane permeability;
• simulating peptide–excipient interactions;
• predicting dissolution and release profiles;
• modelling GI transit and regional exposure;
• integrating formulation variables into pharmacokinetic models.

Machine learning can also support high-throughput screening. Models may use peptide descriptors, formulation composition and experimental permeability data to prioritise the next set of experiments.

However, AI does not remove the need for laboratory validation. Prediction quality depends on the quality and relevance of the training data. A model trained on small molecules, simplified cell monolayers or a narrow range of formulations may not predict the performance of a complex peptide dosage form in human GI conditions.

The most credible direction is therefore hybrid: mechanistic modelling combined with high-quality experimental data. Molecular dynamics can help explain interactions at the membrane or excipient level, while physiologically based pharmacokinetic models can connect those findings to systemic exposure.

What this means for research peptides in the UK

For researchers evaluating research peptides in the UK, route-specific evidence is essential.

A certificate of analysis cannot prove oral bioavailability. Purity testing confirms what is present in the vial. It does not establish that the compound will survive gastric and intestinal conditions or cross the intestinal epithelium.

That is why peptide purity testing in the UK should be treated as one part of research quality control. HPLC can assess chromatographic purity, while mass spectrometry can help confirm molecular identity. Additional studies are required for stability, degradation, dissolution, permeability and pharmacokinetics.

NAD+ also illustrates the need for accurate classification. NAD+ is a coenzyme rather than a peptide, so its stability and absorption questions should not automatically be mapped onto peptide delivery models. The appropriate analytical and pharmacokinetic framework depends on the compound.

At AXIOM Health, we focus on clear compound identity, third-party testing and protocol-led research documentation. For broader background on mechanisms, compound selection and research design, please consult the AXIOM Research Compendium.

Conclusion

Most peptides struggle with oral delivery for three connected reasons:

1. Proteases and peptidases can degrade the molecule before absorption.
2. Mucus and the intestinal epithelium restrict transport.
3. Variable GI conditions create inconsistent pharmacokinetic exposure.

The 2026 research landscape is responding with multi-component systems rather than simple oral capsules. Lipid-based carriers, enteric coatings, permeation enhancers, structural modification and AI-assisted prediction are being combined to improve stability and exposure.

The key point is precision. A peptide’s size, sequence and purity matter, but they do not determine oral bioavailability on their own. Each compound requires route-specific testing under relevant biological and formulation conditions.

For laboratory research, the sensible standard is straightforward: verify identity, verify purity, test stability, measure intact compound and interpret oral exposure cautiously.

Sources

[^1]: Khalid N-U-A, Rivera-Delgado E, von Erlach T. “Navigating the complexity of oral peptide delivery: challenges and strategies to enhance oral bioavailability.” Frontiers in Drug Delivery, 2026.

[^2]: Asano D, Takakusa H, Nakai D. “Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs.” Pharmaceutics, 2024.

[^3]: Brown TD, Whitehead KA, Mitragotri S. “Materials for oral delivery of proteins and peptides.” Nature Reviews Materials, 2020.